We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Merck & Co. and other biopharma players hustled to develop Ebola vaccines amid a devastating West Africa epidemic that started in 2014. Now, before Merck’s shot wins an official license, it could be used to combat a new outbreak in Congo.
A new approach to information gathering could allow scientists to quickly identify the most effective way to manage a disease outbreak, an advance that could save lives.
Even as the WHO said last year that the deadly Ebola outbreak was no longer an international emergency, vaccine experts continue to press officials to not let up in the fight against the virus.